Mescaline for Schizophrenia

2 papers and 0 clinical trials exploring mescaline as a treatment for schizophrenia.

CompoundPhenethylamine

Mescaline

A naturally occurring phenethylamine psychedelic found in certain cacti, investigated for its role in religious practice and psychiatric research.

Full Mescaline profile
IndicationApproximately 24 million people worldwide are affected by schizophrenia.

Schizophrenia

Schizophrenia is a complex psychiatric disorder characterised by disruptions in thought processes and perception. Recent research into psychedelics has opened new avenues for understanding its neurobiology and exploring potential therapeutic mechanisms, particularly in addressing treatment-resistant symptoms.

Full Schizophrenia profile

Academic Research

2 papers
Open Accessindividual

Assessment of the acute effects of 2C-B vs psilocybin on subjective experience, mood and cognition

In a within‑subjects, double‑blind, placebo‑controlled study of 22 psychedelic‑experienced volunteers, 20 mg 2C‑B produced acute psychedelic alterations of moderate experiential depth but elicited less dysphoria, subjective impairment, auditory changes and ego‑dissolution than 15 mg psilocybin. Both drugs produced comparable psychomotor slowing, spatial memory impairments and transient pressor effects, while 2C‑B’s subjective effects were shorter in duration (largely resolving within ~6 hours).

Published
Journal
Clinical Pharmacology and Therapeutics
Authors
Kuypers, K. P. C., Mallaroni, P., Mason, N. L., Paci, R., Ramaekers, J. G., Reckweg, J., Theunissen, E. L., Toennes, S. W.

Clinical Trials

0 trials

No clinical trials have been tagged with both Mescaline and Schizophrenia yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all Mescaline papers Search all Schizophrenia trials Full Mescaline profile Full Schizophrenia profile